Prospective Evaluation of 18F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer in an Academic Center: A Focus on Disease Localization and Changes in Management

Conclusion: 18F-DCFPyL PET/CT is a promising diagnostic tool in the work-up of biochemically recurrent PC, given the high positivity rate as compared with Food and Drug Administration–approved currently available imaging modalities and its impact on clinical management in 60% of patients.

Source: Journal of Nuclear Medicine - March 31, 2020 Category: Nuclear Medicine Authors: Song, H., Harrison, C., Duan, H., Guja, K., Hatami, N., Franc, B. L., Moradi, F., Aparici, C. M., Davidzon, G. A., Iagaru, A. Tags: Clinical Source Type: research